Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
| Product: | Omjjara |
| Active Ingredient: | Momelotinib dihydrochloride monohydrate 121.94mg equivalent to momelotinib 100mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | GlaxoSmithKline NZ Limited |
| Manufacturer: | Patheon Inc, Mississauga, Canada |
| Product: | Omjjara |
| Active Ingredient: | Momelotinib dihydrochloride monohydrate 182.91mg equivalent to momelotinib 150mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | GlaxoSmithKline NZ Limited |
| Manufacturer: | Patheon Inc, Mississauga, Canada |
| Product: | Omjjara |
| Active Ingredient: | Momelotinib dihydrochloride monohydrate 243.88mg equivalent to momelotinib 200mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | GlaxoSmithKline NZ Limited |
| Manufacturer: | Patheon Inc, Mississauga, Canada |
Dated this 21st day of February 2025.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).